REZOLUTE INC (RZLT) Stock News
NASDAQ:RZLT - Nasdaq - US76200L3096 - Common Stock - Currency: USD
RZLT Latest News, Press Relases and Analysis
Rezolute, Inc. (RZLT): Analysts See 260% Upside Potential
We recently published an article titled 13 Best Multibagger Stocks to Invest in Now. Rezolute, Inc. (NASDAQ:RZLT) was one of the stocks that was covered in that article. Wall Street analysts believe RZLT has a 260% upside potential over the next 12 months. Rezolute, Inc. (NASDAQ:RZLT) is a late-stage biopharmaceutical company focused on addressing rare […]
Number Sense: Will retail define SpartanNash’s future?
The grocery solutions company’s retail sales have steadily improved for four straight quarters even as revenue for its much larger wholesale operation has remained in negative territory.
Rezolute Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update
sunRIZE enrollment on track including U.S. sites and expected to be completed in May 2025; topline data anticipated in December 2025 U.S. Food and Drug...
Rezolute Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update
Rezolute to Participate in Upcoming Investor Conferences
REDWOOD CITY, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company...
Rezolute to Participate in Upcoming Investor Conferences
Rezolute, Inc. Announces Closing of Underwritten Offering
Rezolute, Inc. Announces Closing of Underwritten Offering
NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company...
Rezolute 'Thrilled' With Positive Review Of Genetic Disorder Trial, Expects Topline Results In December
Rezolute advances HI drug trial after DMC review and secures $90 million in funding through stock offering to support development.
Rezolute Announces Pricing of Offering of $90 Million of Common Stock and Pre-Funded Warrants
NEW YORK, April 23, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company...
Rezolute Announces Pricing of Offering of $90 Million of Common Stock and Pre-Funded Warrants
Rezolute Announces Appointment of Rare Disease Commercial Leader Erik Harris to its Board of Directors
REDWOOD CITY, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a late-stage biopharmaceutical company dedicated to developing...
Rezolute Announces Appointment of Rare Disease Commercial Leader Erik Harris to its Board of Directors
Rezolute Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update
Ersodetug, a novel, fully human monoclonal antibody for the treatment of hyperinsulinism (HI), receives Breakthrough Therapy Designation and Orphan Drug...
Rezolute Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update
Rezolute Provides Update on its Phase 3 sunRIZE Study of Ersodetug for the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism
Open-label arm (infant participants < 1 year old) has been recently reviewed by a Data Monitoring Committee (DMC) and target drug concentrations were...
Rezolute to Participate in the Guggenheim SMID Cap Biotech Conference
REDWOOD CITY, Calif., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical...
Rezolute to Participate in the Guggenheim SMID Cap Biotech Conference
Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism
Breakthrough Therapy Designation granted based on key positive data from the Phase 2b (RIZE) study and current unmet medical need in congenital...
Rezolute Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
REDWOOD CITY, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical...
Rezolute Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
FDA Grants Orphan Drug Designation to Rezolute’s Ersodetug (RZ358) for the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism
Phase 3 registrational trial for ersodetug in patients with tumor hyperinsulinism (HI) expected to commence in 2025; real-world patient benefit...
FDA Grants Orphan Drug Designation to Rezolute’s Ersodetug (RZ358) for the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism
Phase 3 registrational trial for ersodetug in patients with tumor hyperinsulinism (HI) expected to commence in 2025; real-world patient benefit demonstrated in Expanded Access Program
Rezolute Reports First Quarter Fiscal 2025 Financial Results and Provides Business Update